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AMP-activated protein kinase (AMPK) is a highly conserved sensor
of cellular energy status found in all eukaryotic cells. AMPK is
activated by stimuli that increase the cellular AMPATP ratio.
Essential to activation of AMPK is its phosphorylation at Thr-172 by
an upstream kinase, AMPKK, whose identity in mammalian cells
has remained elusive. Here we present biochemical and genetic
evidence indicating that the LKB1 serinethreonine kinase, the
gene inactivated in the Peutz-Jeghers familial cancer syndrome, is
the dominant regulator of AMPK activation in several mammalian
cell types. We show that LKB1 directly phosphorylates Thr-172 of
AMPK in vitro and activates its kinase activity. LKB1-deficient
murine embryonic fibroblasts show nearly complete loss of Thr-172
phosphorylation and downstream AMPK signaling in response to
a variety of stimuli that activate AMPK. Reintroduction of WT, but
not kinase-dead, LKB1 into these cells restores AMPK activity.
Furthermore, we show that LKB1 plays a biologically significant
role in this pathway, because LKB1-deficient cells are hypersensi-
tive to apoptosis induced by energy stress. On the basis of these
results, we propose a model to explain the apparent paradox that
LKB1 is a tumor suppressor, yet cells lacking LKB1 are resistant to
cell transformation by conventional oncogenes and are sensitive to
killing in response to agents that elevate AMP. The role of LKB1
AMPK in the survival of a subset of genetically defined tumor cells
may provide opportunities for cancer therapeutics.
AMP-activated protein kinase (AMPK) is the primary reg-ulator of the cellular response to lowered ATP levels in
eukaryotic cells (1, 2). AMPK is activated by stimuli that include
pathological stresses, such as oxidative damage, osmotic shock,
hypoxia, and glucose deprivation, as well as physiological stimuli,
such as exercise, muscle contraction, and hormones including
leptin and adiponectin (1). Accordingly, AMPK phosphoryla-
tion of its downstream targets results in the up-regulation of
ATP-producing catabolic pathways and the down-regulation of
ATP-consuming processes. Recent studies have indicated that
AMPK is a critical regulator of leptin-induced fatty acid me-
tabolism and glucose uptake in skeletal muscle (3–5). Indeed,
impaired energy metabolism is a primary defect in type 2
diabetes, and two major current diabetic therapeutics have been
shown to act via stimulation of AMPK (3).
AMPK exists in cells as a heterotrimeric complex composed
of a catalytic kinase subunit () and two regulatory subunits (
and ). Because of the presence of cystathionine  synthase
(CBS) domains, which can act as nucleoside-binding motifs in
other proteins, as well as naturally occurring activating muta-
tions, the  subunit has been proposed to mediate direct binding
of AMP (1). AMP binding has been proposed to induce a
conformational change in the heterotrimeric AMPK that allows
it to serve as a better substrate for an upstream activating
kinase(s). Phosphorylation of a single invariant threonine resi-
due in the activation loop of the catalytic subunit (Thr-172 in
human AMPK1) has been shown to be required to activate all
known AMPK homologues (1). A number of laboratories have
reported biochemical purification of a kinase activity, AMPK
kinase (AMPKK), that is capable of phosphorylating Thr-172
(6–8). Calciumcalmodulin-dependent protein kinase kinase
(CAMKK) has been demonstrated to serve as a surrogate
AMPKK in vitro, although some of its biochemical properties
suggest it may not be a bona fide AMPKK in vivo (9).
The LKB1 serinethreonine kinase is a divergent yet evolu-
tionarily well conserved kinase that most closely resembles
CAMKK in its catalytic domain. LKB1 inactivation is the genetic
basis of Peutz-Jeghers syndrome, a familial colorectal polyp
disorder in which patients are predisposed to early-onset cancers
in other tissues (10). Recently, LKB1 has been shown to be an
essential mediator of embryonic polarity in Caenorhabditis el-
egans and Drosophila (11, 12). STRAD, a recently identified
obligate coactivator for LKB1, is the only known physiological
substrate of LKB1 (13). Because of the homology of LKB1 to
CAMKK, as well as the recently discovered AMPKKs in yeast
(14, 15), we set out to determine whether LKB1 is a bona fide
AMPKK in vivo and whether it regulates AMPK signaling under
physiological circumstances. We present here genetic and bio-
chemical evidence that LKB1 is the major AMPKK in several
mammalian cell types in response to changes in AMPATP
ratios. While an earlier version of this article was in review,
articles appeared by Hawley et al. (16) and Woods et al. (17) that
also support the idea that LKB1 is an AMPKK in vivo.
We further show here that LKB1 is a critical mediator of the
effects of low energy on cell viability. We conclude that LKB1
is essential to protect cells from apoptosis in response to agents
that elevate intracellular AMP and as such may act as a
low-energy checkpoint in the cell. These results suggest a model
to explain the paradox that loss of LKB1 in tumors can result in
increased cell growth, yet LKB1-deficient cells are resistant to
transformation and readily undergo apoptosis under conditions
that elevate AMP.
Materials and Methods
Reagents. HT1080, LLC-PK1, and HeLa cells were all purchased
from the American Type Culture Collection (ATCC). Murine
Abbreviations: AMPK, AMP-activated protein kinase; AMPKK, AMPK kinase; MEF, murine
embryonic fibroblast; ACC, acetyl CoA carboxylase; MBP, maltose-binding protein; AICAR,
5-aminoimidizole-4-carboxamide riboside.
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embryonic fibroblasts (MEFs) were derived from embryos at
postcoitum day 13.5 as previously described (18). LKB1/
MEFs were produced by in vitro excision of the LKB1 lox allele
as previously described (18). Phospho-Thr-172 AMPK, total
AMPK, and phospho-acetyl CoA carboxylase (ACC) antibod-
ies were from Cell Signaling Technology (Beverly, MA). SAMS
peptide was from Upstate Biotechnology (Lake Placid, NY).
Maltose-binding protein (MBP) AMPK (1-312) bacterial fu-
sion protein was prepared and purified as previously described
(7). Heterotrimeric AMPK was expressed in and isolated from
COS cells (7). LKB1 antibody (1G) was previously described
(18). FLAG-tagged human LKB1 was generated by subcloning
the human LKB1 cDNA into an N-terminal-tagged pCDNA3
vector. Human and mouse LKB1 retroviral constructs were
generated by PCR and subcloning into pBABE-puro. Point
mutations were generated by using QuikChange mutagenesis
(Stratagene). STRAD was PCR-amplified from a human EST
(Research Genetics, Huntsville, AL) and subcloned into
pCDNA4HisMax (Invitrogen). All constructs were fully se-
quenced to verify their integrity. Sorbitol, H2O2, and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
were obtained from Sigma, and 5-aminoimidizole-4-carboxam-
ide riboside (AICAR) was obtained from Toronto Research
Chemicals (Downsview, ON, Canada).
Kinase Assays and Cellular Analysis. The kinase activity of AMPK
was measured by using the SAMS peptide as previously de-
scribed (7). LKB1 phosphorylation of AMPK was carried out in
kinase buffer (50 mM Tris, pH 7.510 mM MgCl21 mM
DTT100 m ATP) for 20 min at 30°C. For immunoprecipita-
tions of active LKB1 kinase, FLAG-tagged LKB1 was cotrans-
fected with an equimolar amount of STRAD expression plasmid
into HT1080 cells and immunoprecipitated by using M2-agarose
(Sigma) 24 h posttransfection in Nonidet P-40 lysis buffer (19).
Before kinase assays, immunoprecipitated LKB1 was washed
three times in lysis buffer, then twice in kinase buffer. Soluble
MBP–AMPK was added at 5 g per kinase reaction. The LKB1
peptide library screen was performed as previously described
(20). Peptide libraries were fixed at indicated positions and
degenerate for all amino acids except cysteine, threonine, and
serine at all other positions indicated with an ‘‘x,’’ with at least
four degenerate flanking positions on either side of all fixed
sequences [e.g., the LxT library is composed of x-x-x-x-Leu-x-
Thr-x-x-x peptides with a fixed lysine tail (K-K-K)]. Total cell
extracts and immunoblotting were as previously described (21).
Amphotropic and ecotropic retroviral infections and subsequent
selections were as previously described (22). For the cell survival
assays, cells were plated in triplicate for each condition on
48-well plates. MTT assays were performed according to the
manufacturer’s suggestions (Sigma).
Results
We set out to identify the optimal substrate motif for LKB1 in
an attempt to identify other substrates. To examine the substrate
specificity of LKB1, we coexpressed it in mammalian cells with
its coactivator STRAD and then tested the ability of purified
LKB1 immunoprecipitates to phosphorylate various degenerate
peptide libraries (20). Interestingly, we found that LKB1 will
only phosphorylate libraries with threonine as the phospho-
acceptor site (Fig. 7, which is published as supporting informa-
tion on the PNAS web site). Arginine in the 1 position was
selected over random amino acids, and leucine in the 2 position
was strongly selected, suggesting that a Leu-Arg-Thr motif would
be a highly selected peptide substrate. Thr-172 of AMPK has
a leucine in the 2 position that is conserved in AMPK
orthologues from other species, including the yeast SNF1 protein
(Fig. 1a), and a well conserved arginine in the 1 position,
suggesting it would make an excellent in vitro substrate for LKB1.
In addition, the previously mapped LKB1 phosphorylation sites
in STRAD conform to the LxT sequence.
Given these observations, we investigated whether LKB1
would phosphorylate Thr-172 of AMPK in vitro. As seen in Fig.
1b, WT, but not kinase-dead, LKB1 immunoprecipitated from
mammalian cells efficiently phosphorylated a bacterially ex-
pressed MBP fusion product of the AMPK catalytic subunit in
vitro. Moreover, coexpression of LKB1 with STRAD led to a
dramatic proportional increase in LKB1 autophosphorylation
and transphosphorylation of MBP–AMPK. Immunoblotting
with phosphospecific AMPK Thr-172 antisera confirmed that
LKB1 phosphorylated this site in vitro. As seen in Fig. 1b, the
level of immunoblotting with anti-phospho-Thr-172 antibody
was directly proportional to the amount of 32P incorporation into
recombinant AMPK in a parallel radioactive in vitro kinase
assay.
To examine whether in vitro phosphorylation of AMPK by
LKB1 was sufficient to activate the bacterial MBP–AMPK
fusion protein, we assayed the kinase activity of AMPK by
using a specific peptide substrate, SAMS (14). As previously
reported (7), bacterial MBP–AMPK is inactive toward the
peptide (Fig. 1c). In vitro phosphorylation of AMPK by WT
LKB1 alone or STRAD-activated LKB1 induced the kinase
activity of AMPK by an average of 27- and 50-fold, respectively.
Kinase-dead LKB1 alone or coexpressed with STRAD was
unable to activate AMPK.
Next we addressed whether agonists that activate the kinase
activity of AMPK also serve to stimulate the kinase activity of
LKB1. The MBP–AMPK fusion we used as a substrate is not
stimulated by AMP in vitro (unlike the intact AMPK heterotri-
mer); therefore, any stimulated phosphorylation of this fusion
protein by LKB1 only reflects the kinase activity of LKB1. We
confirmed that AMP stimulates the kinase activity of heterotri-
meric AMPK in vitro (Fig. 8b, which is published as supporting
information on the PNAS web site). In contrast, LKB1 kinase
activity was not directly stimulated in vitro by AMP (Fig. 8a). We
then examined whether LKB1 kinase activity would be increased
in cells treated with the AMPK agonists H2O2 or AICAR.
Peroxide serves to activate AMPK by increasing intracellular
AMPATP ratios. AICAR is a cell-permeable drug that is
converted to AICAR monophosphate (ZMP) intracellularly and
mimics the effect of AMP on AMPK signaling (1). The kinase
activity of LKB1 immunoprecipitated from cells treated with
peroxide or AICAR was not increased compared with that from
untreated control cells, as measured both by autophosphoryla-
tion and transphosphorylation of the MBP–AMPK fusion (Fig.
8a). Both of these treatments led to activation of AMPK in vivo
(see below). These results support a previously suggested model
in which allosteric regulation of the AMPK heterotrimer by
AMP binding allows it to better serve as substrate for the
upstream kinase (2), as opposed to direct regulation of the
activity of the AMPKK by AMP.
As a first means to address whether LKB1 is a bona fide
AMPKK in vivo, we examined whether LKB1 and AMPK
associated in cells. We transfected FLAG-tagged WT and ki-
nase-dead LKB1 or control kinases into HT1080 cells and then
immunoprecipitated with anti-FLAG antisera and immunoblot-
ted for endogenous AMPK. As seen in Fig. 1d, a significant
amount of endogenous AMPK specifically coimmunoprecipi-
tated with kinase-dead LKB1, suggesting that it may act to trap
substrates.
To rigorously test the requirement for LKB1 in AMPK
activation in vivo, we derived LKB1-deficient MEFs from con-
ditionally inactivated mouse embryos as previously described
(18). Cells from littermate-matched embryos then were stimu-
lated with peroxide or AICAR, and the response of AMPK was
examined. As seen in Fig. 2a, LKB1-null MEFs, but not WT or
heterozygous controls, showed a complete loss of stimulated
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Thr-172 phosphorylation in response to peroxide and AICAR.
To determine whether AMPK activity was accordingly down-
regulated in these cells, we examined the in vivo phosphorylation
of one of its critical downstream substrates, ACC. AMPK
inactivates ACC through phosphorylation of Ser-79, thereby
stimulating fatty acid oxidation (1). Mirroring the level of
phospho-AMPK, phosphorylation of ACC in response to both
stimuli was nearly abolished in LKB1-null cells. There was still
a small, but reproducible, amount of ACC phosphorylation in
response to these stimuli in LKB1-null MEFs, suggesting the
existence of other minor compensating AMPKKs in these cells
or the existence of other ACC kinases also activated by these
stimuli. However, the dramatic reduction in phospho-AMPK
and phospho-ACC indicates that LKB1 is the dominant AMPKK
activity in these cells in response to the stimuli tested. To
demonstrate that LKB1 loss itself, and not a secondary defect
arising in these cells, is responsible for impaired AMPK activa-
tion, we reintroduced WT and kinase-dead LKB1 alleles into an
immortalized LKB1-null MEF line by retrovirus. Indeed, WT,
but not kinase-dead, LKB1 expression reconstitutes AMPK
activation (Fig. 2b) and downstream phosphorylation of its
targets (data not shown). Interestingly, despite the absence of
LKB1 in these cells, kinase-dead LKB1 reduced the basal and
stimulated phosphorylation of AMPK and ACC to levels below
the vector-infected control LKB1-null cells, suggesting that
kinase-dead LKB1 might block endogenous AMPK from being
available as a substrate for other compensatory AMPKKs.
Given the requirement for LKB1 in AMPK activation in
MEFs, we examined the ability of LKB1 to modulate AMPK
activation in other cell types. As above, we used retroviruses to
introduce WT or kinase-dead human and mouse LKB1 into a
number of cell types. As seen in Fig. 3, in HT1080 human
fibrosarcoma cells, kinase-dead LKB1 specifically inhibited
AICAR, peroxide, and osmotic shock-induced Thr-172 phos-
phorylation to levels below those seen in the vector-infected
cells. Additionally, expression of WT LKB1 increased the basal
and stimulated level of Thr-172 phosphorylation (Fig. 3). As in
the MEFs, phosphorylation of Ser-79 of ACC is also increased
basally and in response to all stimuli by WT LKB1 overexpres-
sion, further indicating that AMPK activity is regulated by LKB1
in vivo. Similarly, expression of kinase-dead LKB1 nearly abol-
ishes the AMPK-induced phosphorylation of ACC in response
to all three stimuli in HT1080 cells. Similar results were found in
LLC-PK1 and IEC18 epithelial cells, as well as in HeLa cells,
which are deficient in LKB1 protein because of promoter
methylation (24).
To determine whether LKB1 could mediate biological effects
in response to low energy, we investigated whether LKB1 might
modulate cell death under circumstances in which AMPK would
be activated. AMPK activation has been shown to lead to an
inhibition of apoptosis in a number of cell types. Treatment of
quiescent cells with AICAR protects them from glucocorticoid-
induced apoptosis, and AICAR also protects astrocytes and
endothelial cells from cell death in response to different stimuli
(25–28). Furthermore, reduction of AMPK levels was recently
Fig. 1. LKB1 phosphorylates Thr-172 of AMPK in vitro and activates its kinase activity. (a) Lineup of known LKB1 in vitro phosphorylation sites with sites of
phosphorylation in human AMPK and its yeast homologue SNF1 protein (SNF1p). S.c., Saccharomyces cerevisiae; auto, autophosphorylation. (b) HT1080 cells
were transfected with WT or kinase-dead (KD; K78I) LKB1 with or without its coactivating protein, STRAD. As indicated, LKB1 immunoprecipitates were tested
for their ability to transphosphorylate bacterial MBP–AMPK in an in vitro kinase assay. Parallel in vitro kinase assays were performed by using [-32P]ATP
followed by autoradiography or cold ATP followed by immunoblotting for phospho-Thr-172 AMPK (-P-Thr172) and the indicated proteins. WT LKB1
immunoprecipitates were run in duplicate as shown. MBP–AMPK was also tested alone, as indicated. Results are typical of three separate experiments. (c) AMPKK
assay. LKB1 phosphorylation of MBP–AMPK activates its kinase activity toward a peptide substrate (SAMS). LKB1 immunoprecipitates (as in a) were used to
phosphorylate MBP–AMPK in vitro, and then MBP–AMPK was removed and tested for its ability to transphosphorylate the SAMS peptide in the presence of
[-32P]ATP. Results were obtained from two separate experiments in triplicate. LKB1 alone was incapable of detectably phosphorylating the SAMS peptide, and
equivalent levels of LKB1 and MBP–AMPK were used in each reaction (data not shown). Samples without LKB1, without SAMS peptide, or without MBP–AMPK
all gave similar levels of background (data not shown). KD, kinase-dead. (d) Coimmunoprecipitation of endogenous AMPK with LKB1. HT1080 cells were
transfected with FLAG-tagged vectors encoding WT or kinase-dead (KD) LKB1 (with or without STRAD), or FLAG-JNK or FLAG-PKC . FLAG immunoprecipitates
(IPs) were immunoblotted with anti-AMPK pan antisera (Upstate Biotechnology); 5% of the total input is shown at right. A significant amount of endogenous
AMPK coimmunoprecipitates with kinase-dead LKB1. TCEs, total cell extracts.



















shown to reduce cellular viability after glucose deprivation in a
number of human tumor cell lines (28). We therefore compared
the response of LKB1-deficient cells with that of LKB1-
expressing cells as above in their cellular response to apoptotic
stimuli, including stimuli known to activate AMPK. To that end,
we used WT and LKB1-deficient MEFs as well as HeLa cells that
were reconstituted with WT or kinase-dead LKB1 (Fig. 9, which
is published as supporting information on the PNAS web site).
Two independent lines of LKB1-deficient MEFs, but not their
WT littermate controls, underwent rapid apoptosis (12 h)
when treated with AICAR (Fig. 4a). AICAR treatment did
induce some cell death in the WT MEFs, but this death was
delayed until 36 h posttreatment (data not shown). Similar to
MEFs, vector-infected or kinase-dead LKB1-expressing HeLa
cells died rapidly after AICAR treatment, unlike their counter-
parts reconstituted with WT LKB1 (Fig. 4 b and c). In contrast,
UV treatment killed all cell lines regardless of LKB1 status, to
a similar extent (Fig. 4c) and with similar kinetics (data not
shown).
To address whether LKB1-deficient cells might also be sen-
sitive to cell death induced by other AMPK agonists, we treated
MEFs and HeLa cells with peroxide or the mitochondrial
uncoupler oligomycin. Similar to treatment with AICAR, treat-
ment with these agents selectively induced apoptosis in LKB1-
deficient MEFs (data not shown) and HeLa cells (Fig. 4c),
although not as efficiently as AICAR. Finally, we were interested
in whether other AMPK agonists that do not alter AMPATP
ratios would also selectively induce apoptosis in the LKB1-
deficient cells. Metformin is a widely used treatment for type 2
diabetes that has been demonstrated to activate AMPK without
altering intracellular AMP or ATP. We found that, in MEFs,
metformin activated AMPK and that this response was ablated
in the LKB1-deficient cells, as seen for peroxide and AICAR
treatment (data not shown). Strikingly, metformin treatment did
not result in any cell death in the LKB1-deficient HeLa cells (Fig.
4c). This result suggests that elevation of AMP is the critical
event that drives apoptosis in the LKB1-deficient cells.
To begin to examine the mechanism by which death occurs in
the LKB1-deficient cells, we examined the activation of various
signaling pathways in WT or LKB1-deficient MEFs after
AICAR treatment. Caspase-3 was selectively activated in LKB1-
deficient cells after AICAR treatment (Fig. 5), as visualized by
immunoblotting for the presence of activation-specific caspase-3
and cleavage of the caspase-3 substrate poly(ADP-ribose) poly-
merase (PARP). In addition, c-Jun NH2-terminal kinase (JNK)
and p38, but not Erk or Akt, were selectively activated in the
LKB1-null cells. Akt signaling was not suppressed in response to
AICAR. In fact, a slight but consistent increase in phospho-Akt
was observed in both genotypes after AICAR treatment, sug-
gesting that down-regulation of this major survival signaling
pathway is not involved in the cell death observed.
Discussion
Taken together, the results presented here suggest that LKB1 is
a bona fide AMPKK and is the major AMPKK present in a
number of cell types. Moreover, we show that LKB1 protects
cells from apoptosis induced by elevated AMP levels. These
findings provide genetic and biochemical evidence that LKB1 is
a critical regulator of AMPK in vivo. As such, LKB1 may play an
unexpected role in multiple organ systems that mediate the
diverse effects of AMPK on mammalian physiology. Impor-
tantly, AMPK has been shown to be a critical mediator of
glucose uptake in skeletal muscle in mice (5), and the kinase
activity of AMPK is stimulated by two major diabetes therapeu-
tics (29, 30). Therefore, identification of LKB1 as a major
activator of AMPK in vivo may introduce a set of potential
avenues to explore in the effort to boost AMPK activity for the
treatment of diabetes. It will be critical to define the specific
Fig. 2. LKB1-deficient MEFs are defective in AMPK activation. (a) Littermate
MEFs of the indicated LKB1 genotypes were left untreated (n.t.) or were
treated with 0.1 mM H2O2 for 20 min or 2 mM AICAR for 2 h. Total cell extracts
were immunoblotted for phospho-Thr-172 AMPK (P-AMPK) or phospho-
Ser-79 ACC (P-ACC), as well as for total AMPK and LKB1. (b) An immortalized
LKB1-deficient MEF cell line was reconstituted with human (hu) or mouse (ms)
WT (wt) or kinase-dead (kd) LKB1-expressing retroviruses. v, Vector control
cells; hu wt, human FLAG-tagged WT LKB1-expressing cells; hu kd, human
FLAG-tagged kinase-dead LKB1-expressing cells; ms wt, untagged mouse WT
LKB1-expressing cells; ms kd, untagged mouse kinase-dead LKB1-expressing
cells. Cells were treated as in a. The asterisk indicates a background band that
serves as a loading control.
Fig. 3. LKB1 regulates activation of AMPK in response to the AMP analogue
AICAR as well as to oxidative or osmotic stress in HT1080 cells. HT1080 cells
stably expressing WT or kinase-dead (kd) LKB1 as in Fig. 2 were treated with
0.1 mM H2O2 for 20 min, 0.6 M sorbitol for 30 min, or 2 mM AICAR for 2 h. Total
cell extracts were analyzed as in Fig. 2. v, Vector control cells; hu, human; ms,
mouse; P-AMPK, phospho-Thr-172 AMPK; P-ACC, phospho-Ser-79 ACC.
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tissues in which LKB1 serves as the principal AMPKK and to
determine which AMPK-activating stimuli use LKB1 as opposed
to other AMPKKs. The presence of three functionally redundant
AMPKKs in yeast (14, 15), along with the residual AMPK
phosphorylation seen in LKB1-deficient cells, suggests that there
will be additional mammalian AMPKKs.
AMPK is the first identified substrate of the LKB1 tumor
suppressor that may mediate its downstream biological effects.
Interestingly, we have found that multiple disparate types of
LKB1-deficient cells are sensitized to death by the AMP ana-
logue AICAR. These data suggest that LKB1AMPK signaling
plays a role in protection from apoptosis, specifically in response
to agents that increase the cellular AMPATP ratio. We hy-
pothesize that active AMPK signaling offers a protective effect
by allowing the cell time to attempt to reverse the aberrantly high
ratio of AMPATP. If unable to reverse this ratio, the cell
eventually will undergo cell death. However, in the absence of
active AMPK signaling, the onset of this death is rapid, as is
observed in the LKB1-deficient MEFs and HeLa cells. These
results offer the provocative suggestion of a potential therapeutic
window in which LKB1-deficient tumor cells might be acutely
sensitive to AMP analogues or sensitized to cell death by other
stimuli when treated in combination with agents that increase the
AMPATP ratio. Interestingly, the diabetic treatment rosiglita-
zone is known to stimulate AMPK signaling through alterations
in the intracellular AMPATP ratio (30), suggesting that it may
be useful in the treatment of LKB1-deficient tumors as well.
The observation that altered AMPATP ratios result in cell
death in the absence of AMPK signaling indicates that other
cellular proteins that are regulated by AMP may contribute to
the cell death observed. One such enzyme is PFK-1, which
catalyzes the rate-limiting conversion of fructose 6-phosphate to
fructose 1,6 bisphosphate in glycolysis. Perhaps by uncoupling
steps of glycolysis from the ability to reverse the high AMPATP
ratio, loss of AMPK may bypass the pentose phosphate shunt,
altering the total reduction power of the cell by lowering
NADPH levels, and predisposing cells to apoptosis by oxidative
stress (31). In addition, AMPK signaling has been suggested to
regulate mitochondrial biogenesis through stimulation of the
peroxisome-activated receptor  coactivator-1 (PGC-1), which
could mediate some of the protective effects observed (32).
Decreased intracellular glucose due to defective Glut1 recruit-
ment in the absence of AMPK signaling is another possible
contributor to the death observed (33). Further studies will be
needed to delineate the critical mediators of the protective effect
of AMPK on cell death. It is worth noting that several connec-
tions between glucose metabolism and apoptosis have been
examined recently (34–36).
The results presented here lead to the paradox that LKB1 acts
as a tumor suppressor in vivo, yet cells lacking LKB1 are
sensitized to killing by agents that elevate AMP and also cannot
be transformed by Ras (18). A possible explanation for the role
of LKB1 in tumor suppression is suggested by emerging evidence
that AMPK activation negatively regulates the mTOR pathway.
AICAR treatment of cells was recently shown to inhibit the
mTOR pathway (37), and we have found that this effect of
AICAR does not occur in LKB1-deficient MEFs (R.J.S., un-
published data). These results are consistent with AMPK down-
regulating major ATP-consuming processes, such as protein
synthesis. The biochemical basis for the effects of AMPK in
Fig. 4. LKB1 protects cells from apoptosis induced by agents that elevate intracellular AMP. (a) Two independent littermate-matched WT and LKB1-deficient
primary MEF cell lines (plated in triplicate) were treated with 2 mM AICAR for 8 h. Cell viability was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay and expressed as a percentage of untreated controls. Results represent three independent experiments. (Inset) Immunoblot
demonstrating LKB1-deletion. The arrowhead indicates LKB1; the asterisk denotes the background band. (b) Phase-contrast images of HeLa cells stably
expressing vector, WT LKB1, or kinase-dead (KD) LKB1 5 h after treatment with 2.5 mM AICAR. Results represent four independent experiments. (c) LKB1
expression protects HeLa cells from AICAR and peroxide, but not UV-induced cell death. Cell viability is expressed as a percentage of untreated controls and
quantified by MTT assays run in triplicate on indicated HeLa stable cell lines treated with 2.5 mM AICAR, 100 M H2O2, 50 Jcm2 UV, or 10 mM metformin for
12 h. HeLa cells were stably infected with vector, WT LKB1-, or kinase-dead (KD) LKB1-expressing retroviruses as indicated.



















down-regulating mTOR signaling was recently reported to be
through direct phosphorylation of the TSC2 tumor suppressor by
AMPK (38). TSC2 is inactivated in tuberous sclerosis, another
cancer syndrome characterized by a predisposition to hamar-
tomatous polyps. Taken together, these results offer a potential
common biochemical explanation for the clinical similarities
between Peutz-Jeghers syndrome and other hamartomatous
syndromes such as Cowden’s disease and tuberous sclerosis. Loss
of the tumor suppressors mutated in all three of these disorders
(PTEN, TSC1, TSC2, and LKB1) results in aberrant up-
regulation of mTOR signaling under conditions of cellular stress
(e.g., growth factor withdrawal, nutrient deprivation, low energy,
etc.) wherein mTOR signaling is normally inhibited. The result-
ing unregulated protein synthesis and cell growth may result in
the formation of the benign polyps that characterize these three
disorders. Interestingly, the same study (38) demonstrated that
TSC2 is essential for protection from apoptosis induced by
glucose deprivation, analogous to the role of LKB1 in low-energy
apoptosis. Future studies should aim at determining whether loss
of TSC2 phosphorylation by AMPK and subsequently deregu-
lated mTOR signaling is the critical downstream effector of
LKB1 in apoptosis as well as tumorigenesis.
Altogether, these data suggest a model for LKB1 as a
low-energy-checkpoint tumor suppressor (Fig. 6). In WT cells,
LKB1 serves as a sensor to induce AMPK signaling, which
keeps ATP-consuming processes, including macromolecular
synthesis and cell division, from occurring under conditions of
low cellular energy. LKB1-dependent phosphorylation of
AMPK triggers the cell to reverse its lowered energy state by
inhibiting anabolic pathways and stimulating catabolic pro-
cesses. In the absence of the LKB1AMPK sensor, such as is
found in Peutz-Jeghers syndrome patients, growth and prolif-
eration pathways (e.g., mTOR) may be aberrantly elevated
under basal conditions, thereby increasing the tumorigenic
potential of certain cell types. When these cells are challenged
with agonists that further increase the AMPATP ratio, our
results predict that LKB1-deficient cells will selectively un-
dergo cell death. These results may in fact explain the per-
plexing observation that LKB1-deficient MEFs are resistant to
oncogenic transformation (unlike most tumor suppressor-
lacking MEFs, which are sensitized to transformation). Cel-
lular transformation may create a higher energy demand on
the cell, triggering activation of AMPK to fulfill the cell’s
energy needs. In the absence of AMPK signaling to stimulate
ATP production, transformation may be impossible, which
perhaps simply drives LKB1-deficient cells into apoptosis.
LKB1AMPK signaling also may play a role in other cellular
responses to environmental stress. LKB1-deficient MEFs are
resistant to passage-induced senescence (18). Recently,
AMPK activity was found to increase in cells undergoing
senescence (39), and artificial hyperactivation of AMPK pro-
moted senescence in primary human fibroblasts, suggesting
that perhaps a loss of AMPK signaling promotes the immor-
talization of LKB1-deficient MEFs. Finally, defining the po-
tential role of AMPK in tumorigenesis or as a potential
regulator of cellular transformation or senescence will provide
many further insights into the fundamental ties among energy
metabolism, apoptosis, and aberrant cell growth and suggest
chemotherapeutic intervention tailored to genetic defects that
affect this pathway.
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Fig. 5. Caspase-3, JNK, and p38 signaling are hyperactivated in LKB1-null
MEFs in response to AICAR. Immunoblot analysis on LKB1 WT or -null MEFs
without treatment (NT) or 5 h after treatment with 2 mM AICAR. Cleaved
(activated) caspase-3, poly(ADP-ribose) polymerase (PARP), phospho-JNK (P-
JNK), phospho-p38 (P-p38), phospho-AKT (P-AKT; Ser-473), and total Akt were
detected by immunoblotting (Cell Signaling Technology).
Fig. 6. Model for LKB1 as a sensor of low energy and negative regulator of
tumorigenesis and apoptosis. Under basal conditions, LKB1 serves as a sensor of
low energy, keeping ATP-consuming processes including protein synthesis in
check via AMPK phosphorylation of TSC2. In response to stresses such as low
glucose, hypoxia, nutrient deprivation, or mitochondrial poisons, LKB1 phos-
phorylates AMPK, which shuts off ATP-consuming processes and up-regulates
ATP production to offset the elevated AMPATP ratio. This activity prevents the
cells from going into apoptosis in response to elevated AMP. In LKB1-deficient
cells, under some basal conditions, there may be increases in TOR signaling due
to the lack of TSC2 phosphorylation by AMPK, resulting in increased growth or
tumorigenic potential. In response to further increases in intracellular AMP,
these cells have no mechanism to offset the elevated AMP and go straight
into apoptosis.
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